

Illuminada Corripio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8408069/publications.pdf>

Version: 2024-02-01

84
papers

1,803
citations

236925

25
h-index

345221

36
g-index

89
all docs

89
docs citations

89
times ranked

2711
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. <i>Psychological Medicine</i> , 2022, 52, 526-537.	4.5	17
2	Target selection for deep brain stimulation in treatment resistant schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 112, 110436.	4.8	11
3	Different measures for auditory hallucinations in populations with psychosis. The Validation of the Spanish versions of the Auditory Vocal Hallucination Rating Scale (AVHRS) and the Positive and Useful Voices Inquiry (PUVI). <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, 15, 259-271.	1.8	1
4	Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?. <i>Journal of Affective Disorders</i> , 2022, 302, 83-93.	4.1	4
5	The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. <i>European Neuropsychopharmacology</i> , 2022, 57, 105-117.	0.7	4
6	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 32-42.	2.0	15
7	The network structure of cognitive deficits in first episode psychosis patients. <i>Schizophrenia Research</i> , 2022, 244, 46-54.	2.0	2
8	The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory. <i>Psychological Medicine</i> , 2021, 51, 2044-2053.	4.5	4
9	Structural brain abnormalities in borderline personality disorder correlate with clinical severity and predict psychotherapy response. <i>Brain Imaging and Behavior</i> , 2021, 15, 2502-2512.	2.1	9
10	Trajectories of suicidal ideation after first episode psychosis: a growth mixture modeling approach. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 418-433.	4.5	17
11	Structure and Functioning of Acute Inpatient Psychiatric Units in Spain: Qualitative Study. <i>JMIR Research Protocols</i> , 2021, 10, e26214.	1.0	0
12	The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2474.	2.4	10
13	Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. <i>European Neuropsychopharmacology</i> , 2021, 47, 112-129.	0.7	20
14	Grey matter microstructural alterations in schizophrenia patients with treatment-resistant auditory verbal hallucinations. <i>Journal of Psychiatric Research</i> , 2021, 138, 130-138.	3.1	5
15	The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds. <i>European Neuropsychopharmacology</i> , 2021, 47, 98-111.	0.7	21
16	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2021, 14, 164-176.	0.3	3
17	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2021, 14, 164-176.	1.8	13
18	The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years. <i>European Neuropsychopharmacology</i> , 2021, 49, 54-68.	0.7	12

#	ARTICLE	IF	CITATIONS
19	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. <i>Schizophrenia Research</i> , 2021, 236, 19-28.	2.0	5
20	Predictors of response to pharmacological treatments in treatment-resistant schizophrenia – A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2021, 236, 123-134.	2.0	10
21	Cognitive clusters in first-episode psychosis. <i>Schizophrenia Research</i> , 2021, 237, 31-39.	2.0	10
22	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 73.	2.4	14
23	Deep brain stimulation in treatment resistant schizophrenia: A pilot randomized cross-over clinical trial. <i>EBioMedicine</i> , 2020, 51, 102568.	6.1	50
24	S229. THE EFFECT OF FAMILY ENVIRONMENT ON LONGITUDINAL FUNCTIONING IN FIRST PSYCHOTIC EPISODES. <i>Schizophrenia Bulletin</i> , 2020, 46, S125-S126.	4.3	0
25	Positive and Useful Voices in Patients With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2020, 208, 587-592.	1.0	3
26	A Method to Compare the Delivery of Psychiatric Care for People with Treatment-Resistant Schizophrenia. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7527.	2.6	3
27	Brain metabolic changes in patients with treatment resistant schizophrenia treated with deep brain stimulation: A series of cases. <i>Journal of Psychiatric Research</i> , 2020, 127, 57-61.	3.1	8
28	Examining Gene-Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. <i>Schizophrenia Bulletin</i> , 2020, 46, 1019-1025.	4.3	32
29	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. <i>Journal of Psychopharmacology</i> , 2020, 34, 514-523.	4.0	12
30	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. <i>Schizophrenia Research</i> , 2020, 218, 292-294.	2.0	6
31	Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 786-794.	0.7	16
32	Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease. <i>American Journal of Neuroradiology</i> , 2019, 40, 1464-1468.	2.4	15
33	Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review. <i>JMIR Mental Health</i> , 2019, 6, e9819.	3.3	90
34	T237. USER EXPERIENCE TOWARDS AN INTEGRAL INTERVENTION MODEL BASED ON M-HEALTH SOLUTION FOR PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA (M-RESIST): QUALITATIVE INFORMATION FROM PATIENTS, CAREGIVERS AND CLINICIANS IN A PILOT STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S208-S209.	4.3	0
35	Smoking does not impact social and non-social cognition in patients with first episode psychosis. <i>Schizophrenia Research</i> , 2018, 199, 64-74.	2.0	13
36	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. <i>Psychological Medicine</i> , 2018, 48, 2247-2256.	4.5	40

#	ARTICLE	IF	CITATIONS
37	Gray and white matter changes and their relation to illness trajectory in first episode psychosis. <i>European Neuropsychopharmacology</i> , 2018, 28, 392-400.	0.7	15
38	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. <i>Schizophrenia Research</i> , 2018, 193, 188-196.	2.0	50
39	Emotional fMR auditory paradigm demonstrates normalization of limbic hyperactivity after cognitive behavior therapy for auditory hallucinations. <i>Schizophrenia Research</i> , 2018, 193, 304-312.	2.0	9
40	Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 699-711.	3.2	31
41	F245. COGNITIVE RESERVE DIFFERENCE IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S318-S318.	4.3	0
42	Impact of <i>NTRK2</i> , <i>DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. <i>Journal of Psychopharmacology</i> , 2018, 32, 702-710.	4.0	8
43	Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers. <i>BMJ Open</i> , 2018, 8, e021346.	1.9	11
44	Cognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 441-455.	4.5	66
45	Affective versus non-affective first episode psychoses: A longitudinal study. <i>Journal of Affective Disorders</i> , 2018, 238, 297-304.	4.1	26
46	Validation of a Spanish version of the Schizotypal Personality Questionnaire (SPQ): Psychometric characteristics and underlying factor structure derived from a healthy university student sample. <i>Actas Espanolas De Psiquiatria</i> , 2018, 46, 159-73.	0.1	2
47	Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations. <i>Schizophrenia Research</i> , 2017, 189, 97-103.	2.0	43
48	Cannabis use, COMT, BDNF and age at first-episode psychosis. <i>Psychiatry Research</i> , 2017, 250, 38-43.	3.3	26
49	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. <i>Schizophrenia Research</i> , 2017, 189, 84-90.	2.0	49
50	Gene-environment interaction as a predictor of early adjustment in first episode psychosis. <i>Schizophrenia Research</i> , 2017, 189, 196-203.	2.0	13
51	Modelling gene-environment interaction in first episodes of psychosis. <i>Schizophrenia Research</i> , 2017, 189, 181-189.	2.0	43
52	Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis. <i>Psychological Medicine</i> , 2017, 47, 1573-1584.	4.5	64
53	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2017, 27, 647-656.	0.7	13
54	Volumetric and morphological characteristics of the hippocampus are associated with progression to schizophrenia in patients with first-episode psychosis. <i>European Psychiatry</i> , 2017, 45, 1-5.	0.2	25

#	ARTICLE	IF	CITATIONS
55	Persistent Negative Symptoms in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1414-1422.	2.2	28
56	m-RESIST, a complete m-Health solution for patients with treatment-resistant schizophrenia: a qualitative study of user needs and acceptability in the Barcelona metropolitan area. <i>Actas Espanolas De Psiquiatria</i> , 2017, 45, 277-89.	0.1	5
57	Letter to the Editor: Deep brain stimulation for schizophrenia. <i>Journal of Neurosurgery</i> , 2016, 125, 229-230.	1.6	8
58	Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. <i>European Psychiatry</i> , 2016, 38, 61-69.	0.2	17
59	Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. <i>NeuroImage: Clinical</i> , 2016, 11, 770-779.	2.7	25
60	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. <i>Pharmacogenomics Journal</i> , 2016, 16, 439-445.	2.0	30
61	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv121.	2.1	29
62	Clinical Improvement in a Treatment-Resistant Patient With Schizophrenia Treated With Deep Brain Stimulation. <i>Biological Psychiatry</i> , 2016, 80, e69-e70.	1.3	27
63	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. <i>PLoS ONE</i> , 2016, 11, e0160949.	2.5	22
64	Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study. <i>JMIR MHealth and UHealth</i> , 2016, 4, e112.	3.7	23
65	Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?. <i>Journal of Dual Diagnosis</i> , 2015, 11, 153-160.	1.2	19
66	Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. <i>Schizophrenia Research</i> , 2015, 161, 261-268.	2.0	106
67	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. <i>Schizophrenia Research</i> , 2015, 164, 65-73.	2.0	92
68	Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2014, 7, 166-178.	0.3	5
69	Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra. <i>Revista De Psiquiatria Y Salud Mental</i> , 2014, 7, 166-178.	1.8	9
70	Double-Blind, Placebo-Controlled Study of the Efficacy of Reboxetine and Citalopram as Adjuncts to Atypical Antipsychotics for Negative Symptoms of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 608-615.	2.2	15
71	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. <i>Psychiatry Research</i> , 2012, 200, 693-701.	3.3	29
72	Altered default network resting state functional connectivity in patients with a first episode of psychosis. <i>Schizophrenia Research</i> , 2012, 139, 13-18.	2.0	56

#	ARTICLE	IF	CITATIONS
73	The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: Iodine-123-iodobenzamide single photon emission computed tomography study. <i>Psychiatry Research - Neuroimaging</i> , 2012, 201, 73-77.	1.8	14
74	Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study. <i>Schizophrenia Research</i> , 2011, 129, 169-171.	2.0	13
75	Density of striatal D2 receptors in untreated first-episode psychosis: An I123-IBZM SPECT study. <i>European Neuropsychopharmacology</i> , 2011, 21, 861-866.	0.7	17
76	Predictors of schizophrenia in patients with a first episode of psychosis. <i>Psychiatry Research</i> , 2010, 175, 11-14.	3.3	12
77	Clinical and serotonergic predictors of non-effective acute remitting psychosis in patients with a first episode psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 71-77.	4.5	10
78	Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. <i>Journal of Psychopharmacology</i> , 2008, 22, 882-894.	4.0	29
79	Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. <i>NeuroImage</i> , 2006, 29, 662-666.	4.2	38
80	Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. <i>Psychopharmacology</i> , 2006, 189, 145-153.	3.1	43
81	Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response. <i>Psychiatry Research - Neuroimaging</i> , 2006, 148, 175-183.	1.8	19
82	Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 91-96.	4.8	19
83	SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1301-9.	5.0	41
84	Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 767-770.	4.8	12